A randomized trial of collaborative support for opioid taper after trauma hospitalization.

IF 3 3区 医学 Q2 SUBSTANCE ABUSE
Mark D Sullivan, Laura Katers, Jin Wang, Sam Arbabi, David Tauben, Laura-Mae Baldwin
{"title":"A randomized trial of collaborative support for opioid taper after trauma hospitalization.","authors":"Mark D Sullivan, Laura Katers, Jin Wang, Sam Arbabi, David Tauben, Laura-Mae Baldwin","doi":"10.1186/s13011-024-00613-x","DOIUrl":null,"url":null,"abstract":"<p><p>The COTAT (Collaborative Opioid Taper After Trauma) Study was a randomized trial of an opioid taper support program using a physician assistant (PA) to provide pain and opioid treatment guidance to primary care providers assuming care for adult patients with moderate to severe trauma discharged from a Level I trauma center on opioid therapy. Patients were recruited, assessed, and randomized individually by a surgery research recruitment team one to two days prior to discharge to home. Participants randomized to the opioid taper support program were contacted by phone within a few days of discharge by the PA interventionist to confirm enrollment and their primary care provider (PCP). The intervention consisted of PA support as needed to the PCP concerning pain and opioid care at weeks 1, 2, 4, 8, 12, 16, and 20 after discharge or until the PCP office indicated they no longer needed support or the patient had tapered off opioids. The PA was supervised by a pain physician-psychiatrist, a family physician, and a trauma surgeon. Patients randomized to usual care received standard hospital discharge instructions and written information on managing opioid medications after discharge. Trial results were analyzed using repeated measures analysis. 37 participants were randomized to the intervention and 36 were randomized to usual care. The primary outcomes of the trial were pain, enjoyment, general activity (PEG score) and mean daily opioid dose at 3 and 6 months after hospital discharge. Treatment was unblinded but assessment was blinded. No significant differences in PEG or opioid outcomes were noted at either time point. Physical function at 3 and 6 months and pain interference at 6 months were significantly better in the usual care group. No significant harms of the intervention were noted. COVID-19 (corona virus 2019) limited recruitment of high-risk opioid tolerant subjects, and limited contact between the PA interventionist and the participants and the PCPs. Our opioid taper support program failed to improve opioid and pain outcomes, since both control and intervention groups tapered opioids and improved PEG scores after discharge. Future trials of post-trauma opioid taper support with populations at higher risk of persistent opioid use are needed. This trial is registered at clinicaltrials.gov under NCT04275258 19/02/2020. This trial was funded by a grant from the Centers for Disease Control and Prevention to the University of Washington Harborview Injury Prevention & Research Center (R49 CE003087, PI: Monica S. Vavilala, MD). The funder had no role in the analysis or interpretation of the data.</p>","PeriodicalId":22041,"journal":{"name":"Substance Abuse Treatment, Prevention, and Policy","volume":"19 1","pages":"33"},"PeriodicalIF":3.0000,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11197264/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Substance Abuse Treatment, Prevention, and Policy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13011-024-00613-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}
引用次数: 0

Abstract

The COTAT (Collaborative Opioid Taper After Trauma) Study was a randomized trial of an opioid taper support program using a physician assistant (PA) to provide pain and opioid treatment guidance to primary care providers assuming care for adult patients with moderate to severe trauma discharged from a Level I trauma center on opioid therapy. Patients were recruited, assessed, and randomized individually by a surgery research recruitment team one to two days prior to discharge to home. Participants randomized to the opioid taper support program were contacted by phone within a few days of discharge by the PA interventionist to confirm enrollment and their primary care provider (PCP). The intervention consisted of PA support as needed to the PCP concerning pain and opioid care at weeks 1, 2, 4, 8, 12, 16, and 20 after discharge or until the PCP office indicated they no longer needed support or the patient had tapered off opioids. The PA was supervised by a pain physician-psychiatrist, a family physician, and a trauma surgeon. Patients randomized to usual care received standard hospital discharge instructions and written information on managing opioid medications after discharge. Trial results were analyzed using repeated measures analysis. 37 participants were randomized to the intervention and 36 were randomized to usual care. The primary outcomes of the trial were pain, enjoyment, general activity (PEG score) and mean daily opioid dose at 3 and 6 months after hospital discharge. Treatment was unblinded but assessment was blinded. No significant differences in PEG or opioid outcomes were noted at either time point. Physical function at 3 and 6 months and pain interference at 6 months were significantly better in the usual care group. No significant harms of the intervention were noted. COVID-19 (corona virus 2019) limited recruitment of high-risk opioid tolerant subjects, and limited contact between the PA interventionist and the participants and the PCPs. Our opioid taper support program failed to improve opioid and pain outcomes, since both control and intervention groups tapered opioids and improved PEG scores after discharge. Future trials of post-trauma opioid taper support with populations at higher risk of persistent opioid use are needed. This trial is registered at clinicaltrials.gov under NCT04275258 19/02/2020. This trial was funded by a grant from the Centers for Disease Control and Prevention to the University of Washington Harborview Injury Prevention & Research Center (R49 CE003087, PI: Monica S. Vavilala, MD). The funder had no role in the analysis or interpretation of the data.

创伤住院后阿片类药物减量协作支持随机试验。
COTAT(创伤后阿片类药物减量协作研究)是一项阿片类药物减量支持计划的随机试验,该计划由一名医生助理(PA)为初级医疗服务提供者提供疼痛和阿片类药物治疗指导,初级医疗服务提供者负责护理从一级创伤中心出院并接受阿片类药物治疗的中重度创伤成人患者。手术研究招募小组在患者出院回家前一到两天对其进行招募、评估和随机分组。被随机选入阿片类药物减量支持计划的参与者会在出院后几天内通过电话与其初级保健医生(PCP)取得联系,以确认是否加入该计划。干预措施包括在出院后的第 1、2、4、8、12、16 和 20 周,或在初级保健医生办公室表示不再需要支持或患者已逐渐停用阿片类药物之前,根据需要向初级保健医生提供有关疼痛和阿片类药物护理的 PA 支持。助理医师由疼痛科精神科医生、家庭医生和创伤外科医生共同监督。随机接受常规护理的患者会收到标准的出院指导和出院后管理阿片类药物的书面信息。试验结果采用重复测量分析法进行分析。37 名参与者被随机纳入干预方案,36 名参与者被随机纳入常规护理方案。试验的主要结果是出院后 3 个月和 6 个月的疼痛、愉悦、一般活动(PEG 评分)和阿片类药物的平均日剂量。治疗无盲法,但评估有盲法。两个时间点的 PEG 或阿片类药物治疗效果均无明显差异。常规护理组在 3 个月和 6 个月时的身体功能以及 6 个月时的疼痛干扰均明显优于常规护理组。未发现干预有明显危害。COVID-19(日冕病毒 2019)限制了高风险阿片类药物耐受受试者的招募,并限制了 PA 干预人员与受试者和初级保健医生之间的接触。我们的阿片类药物减量支持计划未能改善阿片类药物和疼痛结果,因为对照组和干预组在出院后都减少了阿片类药物并改善了PEG评分。今后还需要对持续使用阿片类药物风险较高的人群进行创伤后阿片类药物减量支持试验。该试验已于 2020 年 2 月 19 日在 clinicaltrials.gov 上注册,注册号为 NCT04275258。本试验由美国疾病控制与预防中心向华盛顿大学哈伯维尤伤害预防与研究中心(R49 CE003087,PI:Monica S. Vavilala,医学博士)拨款资助。资助方不参与数据分析或解释。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.20
自引率
0.00%
发文量
73
审稿时长
19 weeks
期刊介绍: Substance Abuse Treatment, Prevention, and Policy is an open access, peer-reviewed journal that encompasses research concerning substance abuse, with a focus on policy issues. The journal aims to provide an environment for the exchange of ideas, new research, consensus papers, and critical reviews, to bridge the established fields that share a mutual goal of reducing the harms from substance use. These fields include: legislation pertaining to substance use; correctional supervision of people with substance use disorder; medical treatment and screening; mental health services; research; and evaluation of substance use disorder programs.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信